Literature DB >> 2130558

Reductase inhibitor therapy of hypercholesterolemia.

R A Kreisberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2130558      PMCID： PMC2376652     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN： 0065-7778


× No keyword cloud information.
  17 in total

1.  Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly?

Authors:  R Benfante; D Reed
Journal:  JAMA       Date:  1990-01-19       Impact factor: 56.272

2.  Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia.

Authors:  J F Bridgman; S M Rosen; J M Thorp
Journal:  Lancet       Date:  1972-09-09       Impact factor: 79.321

3.  Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin.

Authors:  W H Farnsworth; J M Hoeg; M Maher; E H Brittain; R J Sherins; H B Brewer
Journal:  J Clin Endocrinol Metab       Date:  1987-09       Impact factor: 5.958

4.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

5.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

6.  The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway.

Authors:  L Laue; J M Hoeg; K Barnes; D L Loriaux; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1987-03       Impact factor: 5.958

7.  Cholesterol and mortality. 30 years of follow-up from the Framingham study.

Authors:  K M Anderson; W P Castelli; D Levy
Journal:  JAMA       Date:  1987-04-24       Impact factor: 56.272

8.  Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia.

Authors:  M J Malloy; J P Kane; S T Kunitake; P Tun
Journal:  Ann Intern Med       Date:  1987-11       Impact factor: 25.391

9.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.

Authors:  D H Blankenhorn; S A Nessim; R L Johnson; M E Sanmarco; S P Azen; L Cashin-Hemphill
Journal:  JAMA       Date:  1987-06-19       Impact factor: 56.272

10.  Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.

Authors:  D R Illingworth; S Bacon
Journal:  Circulation       Date:  1989-03       Impact factor: 29.690
View more
  1 in total

Review 1.  Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.

Authors:  Christian Henninger; Gerhard Fritz
Journal:  Cell Death Dis       Date:  2017-01-19       Impact factor: 8.469
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.